Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Director Brian K. Halak sold 245,096 shares of the firm’s stock in a transaction dated Tuesday, October 30th. The stock was sold at an average price of $13.92, for a total value of $3,411,736.32. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of NASDAQ DRNA opened at $13.49 on Friday. Dicerna Pharmaceuticals Inc has a one year low of $6.80 and a one year high of $17.98. The company has a quick ratio of 5.40, a current ratio of 5.40 and a debt-to-equity ratio of 0.14.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.26). Dicerna Pharmaceuticals had a negative return on equity of 97.39% and a negative net margin of 1,642.81%. The firm had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $1.79 million. Equities research analysts forecast that Dicerna Pharmaceuticals Inc will post -1.13 EPS for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the company. Cubist Systematic Strategies LLC purchased a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter worth about $102,000. Jane Street Group LLC purchased a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter worth about $136,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Dicerna Pharmaceuticals during the 2nd quarter worth about $178,000. Verition Fund Management LLC purchased a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter worth about $141,000. Finally, Metropolitan Life Insurance Co. NY purchased a new stake in shares of Dicerna Pharmaceuticals during the 2nd quarter worth about $188,000. 74.46% of the stock is owned by institutional investors.
A number of equities research analysts have commented on the company. HC Wainwright raised their price objective on Dicerna Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday. Citigroup restated a “buy” rating and set a $30.00 price objective (up from $27.00) on shares of Dicerna Pharmaceuticals in a research report on Monday, October 29th. ValuEngine lowered Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 19th. BidaskClub lowered Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 9th. Finally, B. Riley raised their price objective on Dicerna Pharmaceuticals from $10.00 to $13.50 and gave the stock a “neutral” rating in a research report on Monday, September 17th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $19.86.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.
Featured Story: Dollar Cost Averaging
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.